Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 16;20(6):e0326106.
doi: 10.1371/journal.pone.0326106. eCollection 2025.

Physicochemical quality assessment of four asparaginases

Vanessa Radtke  1 , Thorsten König  1 , Christoph Radcke  2 , Ulf Bergmann  3 , Rene Eichler  4 , Katja J Pohl  4 , Arndt Schnuchel  1
Affiliations

Physicochemical quality assessment of four asparaginases

Vanessa Radtke et al. PLoS One. .

Abstract

L-Asparaginases (ASNases) are used for the treatment of acute lymphoblastic leukaemia. There are reports of quality problems for some therapeutic asparaginase products, especially those manufactured in middle-income countries. These products may exhibit decreased potency and/or decreased specific activity, or an elevated level of impurities such as host cell proteins. In this study, four different ASNase preparations that were not modified with polyethylene glycol were compared in detail regarding their quality: Spectrila®, Celginase™, Bionase®, and L-Aspase®. Samples were analyzed for protein content, impurities, and enzyme activity. Various chromatographic methods as well as mass spectrometry were used to assess purity and identity. Sample protein content, host cell protein, and enzyme activity showed some results that were out of target range for Celginase™ and Bionase®. These ASNase preparations also showed detectable levels of endotoxins. In gel electrophoresis, additional bands were found for Bionase®. Size exclusion chromatography showed increased high and low molecular weight species for Bionase® and L-Aspase®, and reversed-phase chromatography showed increased hydrophilic and hydrophobic species for Bionase®. In capillary zone electrophoresis, increased retention time for L-Aspase® and increased levels of charge variants for Bionase®, Celginase™, and L-Aspase® were seen. ASNase quality standards are crucial to ensure patient safety and product efficacy, as decreased potency and specific activity may affect efficacy in acute lymphoblastic leukaemia treatment, and increased impurities may affect immunogenicity. Out of four ASNase preparations tested in this study, only Spectrila® did not raise any quality concerns. The other three products exhibited quality problems, rendering them unsuitable according to established quality requirements defined in European and US guidelines for pharmaceutical development of parenteral drug products.

PubMed Disclaimer

Conflict of interest statement

Spectrila® is a pharmaceutical product developed and marketed by medac GmbH in several countries including the European Union. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. a Non-reducing SDS-PAGE of test samples and
b Reducing SDS-PAGE of test samples. Molecular weights of the protein markers are indicated in kDa.
Fig 2
Fig 2. Size exclusion chromatograms of test samples.
Zoomed-in view of the peak integration at low signal intensity, and overlay of all four asparaginases. The peaks at 22–23 minutes that were detected for all asparaginases correspond to salt peaks (column dead volume).
Fig 3
Fig 3. RP-HPLC chromatograms of test samples.
Only the part of the chromatograms with the peaks of interest is shown (20–45 minutes). The peaks at 41 minutes that were detected for all asparaginases were also found in blank samples and are not caused by asparaginase samples.
Fig 4
Fig 4. a Overlay of electropherograms and
b Electropherogram of 1:1 mixture of L-Aspase® and Spectrila®.
See this image and copyright information in PMC

References

    1. Brumano LP, da Silva FVS, Costa-Silva TA, Apolinário AC, Santos JHPM, Kleingesinds EK, et al. Development of L-Asparaginase biobetters: current research status and review of the desirable quality profiles. Front Bioeng Biotechnol. 2019;6:212. doi: 10.3389/fbioe.2018.00212 - DOI - PMC - PubMed
    1. Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G, et al. Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. Haematologica. 2017;102(10):1727–38. doi: 10.3324/haematol.2017.165845 - DOI - PMC - PubMed
    1. Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Ann N Y Acad Sci. 2014;1329:81–92. doi: 10.1111/nyas.12496 - DOI - PubMed
    1. Qin X, Costa-Silva TA, Pessoa A, Long PF. A scoping review to compare and contrast quality assurance aspects of l-asparaginase biosimilars. Int J Pharm. 2023;632:122523. doi: 10.1016/j.ijpharm.2022.122523 - DOI - PubMed
    1. Pieters R, Appel I, Kuehnel H-J, Tetzlaff-Fohr I, Pichlmeier U, van der Vaart I, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112(13):4832–8. doi: 10.1182/blood-2008-04-149443 - DOI - PubMed

MeSH terms

LinkOut - more resources